- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07279376
Evaluating an Algorithm-Based Implementation Strategy to Improve HIV Care Outcomes
January 23, 2026 updated by: Sarit Golub, Hunter College of City University of New York
Harnessing Data Science to Improve HIV Care Continuum Outcomes: A Hybrid Type 2 Trial Evaluating a Machine-Learning Algorithm-Based Implementation Strategy
This study tests a strategy for helping Care Management Agencies prioritize patients with HIV (PWH) for outreach and support.
Under the new strategy, care managers are given a list of highest-priority patients who have been identified by a computer algorithm as being at high risk of going to the emergency room in the next two weeks.
This strategy is compared to traditional (standard of care) care management, in which care managers reach out to patients based on a set schedule and their clinical judgement (but not based on a computerized report).
We are looking at whether the use of the computer report helps care managers reach the right patients at the right time, preventing them from having to go to the emergency room.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Comprehensive Care Management and Care Coordination (CCM/CC) is a medical case management intervention with demonstrated effectiveness in reducing ED visits and hospitalization for PWH, and improving both health outcomes (viral load, CD4 count) and retention in care.
However, despite CCM/CC's effectiveness, there are persistent challenges to its implementation.
This project is based on the scientific premise that the effectiveness of the CCM/CC intervention can be greatly improved by utilizing a data-driven implementation strategy that optimizes timely provision of CCM/CC services to the patients who need it most.
Our community-based collaborator, Comprehensive Care Management Partners (CCMP) Health Home, has developed and validated a machine-learning algorithm that can reliably predict which of its PWH patients are most likely to visit the ED in the next two weeks.
In this project, we will apply this algorithm as a targeted implementation strategy for CCM/CC, focusing service provision on the PWH who need it most, when they need it most.
Our core hypothesis (supported by preliminary studies data) is that this "just-in-time" strategy for implementing a care management intervention will overcome both provider-level barriers to the provision of CCM/CC services and patient-level barriers to the receipt of HIV treatment and care.
We will conduct a Hybrid 2 implementation-effectiveness trial, guided by the RE-AIM implementation science framework and the behavioral economics theory of Scarcity to collect rigorous data on the impact of this algorithm-driven implementation strategy on the reach, effectiveness, adoption, implementation and maintenance of the CCM/CC intervention
Study Type
Interventional
Enrollment (Estimated)
2600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Community Care Management Partners Health Home
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Study Population
All care management agencies that comprise the Community Care Management Partners (CCMP) Health Home and serve patient with HIV will be included.
Randomization occurs at the level of the Care Management Agency.
Data will be extracted from the CCMP electronic medical record on all PWH patients (approximately 2600) in the Health Home.
Description
Inclusion Criteria:
- Participants must be members of one of the Care Management Agencies that comprise the Community Care Management Partners (CCMP) Health Home
- Participants must be living with HIV
Exclusion Criteria:
- None, other than those listed above.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Predictive Emergency Room Alerts (perA)Implementation Strategy
Refers to patients within Care Management Agencies that have been randomized to use the pERA implementation strategy to delivery CCM/CC during that study period.
|
pERA is a machine-learning algorithm-driven implementation strategy that identifies patients at higher risk of emergency room visits and alerts the care manager to follow-up with them.
|
|
Other: Standard of Care Implementation Strategy
Refers to patients in Care Management Agencies that have been randomized to use their standard of care implementation strategy to deliver CCM/CC during that study period.
|
Care managers interact with patients according to their standard of care protocols
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ER visits
Time Frame: Each 18 month cluster period (36 months total)
|
Number of ER visits made by patients
|
Each 18 month cluster period (36 months total)
|
|
Hospitalizations
Time Frame: Each 18 month Cluster Period (36 months total)
|
Number of days of Hospitalization
|
Each 18 month Cluster Period (36 months total)
|
|
Viral Suppression
Time Frame: Each 18 month cluster period (36 months total)
|
Number of timepoints at which patient was virally suppressed
|
Each 18 month cluster period (36 months total)
|
|
CD4 Count
Time Frame: Each 18 month Cluster Period (36 months total)
|
CD4 Level at each data collection timepoint
|
Each 18 month Cluster Period (36 months total)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sarit A. Golub, PhD, MPH, Hunter College of The City University of New York
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2025
Primary Completion (Estimated)
February 1, 2029
Study Completion (Estimated)
August 1, 2029
Study Registration Dates
First Submitted
December 9, 2025
First Submitted That Met QC Criteria
December 9, 2025
First Posted (Actual)
December 12, 2025
Study Record Updates
Last Update Posted (Actual)
January 27, 2026
Last Update Submitted That Met QC Criteria
January 23, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Slow Virus Diseases
- HIV Infections
- Pathological Conditions, Signs and Symptoms
- Emergencies
- Acquired Immunodeficiency Syndrome
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
- R01MH136903 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
State health department requirements regarding these electronic medical record data prohibit sharing IPD.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV (Human Immunodeficiency Virus)
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
Indiana UniversityNational Institute on Aging (NIA)Enrolling by invitationHIV | Geriatric | Geriatric Assessment | HIV - Human Immunodeficiency Virus | HIV (Human Immunodeficiency Virus)United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
RTI InternationalCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) PositiveUnited States
-
Bristol-Myers SquibbCompleted
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, South Africa, Thailand, Colombia, Mexico, Russia
-
Janssen Inc.CompletedHuman Immunodeficiency Virus (HIV)Canada
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID); New York University and other collaboratorsCompletedHIV (Human Immunodeficiency Virus)Swaziland
-
Columbia UniversityMinistry of Health, SwazilandCompleted
Clinical Trials on predictive emergency room alerts (pERA)
-
Evidation HealthBiomedical Advanced Research and Development AuthorityActive, not recruitingCOVID-19 | Influenza | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza BUnited States
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Sohag UniversityNot yet recruiting
-
University Hospital PadovaUniversity of PadovaCompletedHypoglycemia | Glycogen Storage Disease | Congenital Hyperinsulinism (CHI)Italy
-
Shanghai 6th People's HospitalCompleted
-
Jewish General HospitalActive, not recruitingOlder People | Health Care | Health Impairment | EvaluationsCanada
-
Centre Hospitalier Universitaire de NīmesSociete Française de Medecine d'urgenceNot yet recruitingShock | Critical Illness | Respiratory Failure | Resuscitation | Trauma (Including Fractures) | Emergency Department Patient
-
King's College LondonGuy's and St Thomas' NHS Foundation Trust; South London and Maudsley NHS Foundation... and other collaboratorsUnknownClinical Skills TrainingUnited Kingdom
-
Hospital for Special Surgery, New YorkNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of OuluOulu University HospitalCompletedRespiratory Tract InfectionsFinland